Metallothionein-I+II and receptor megalin are altered in relation to oxidative stress in cerebral lymphomas

Leukemia and Lymphoma

Volumn 51, Issue 2, 2010, Pages 314-328

  Pedersen, Mie Ø ^a   Hansen, Per B ^b   Nielsen, Signe L ^b   Penkowa, Milena ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Hematology; Neoplasm; Neuropathology; Oxidative stress

Indexed keywords

MEGALIN; METALLOTHIONEIN I; METALLOTHIONEIN II;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BRAIN LYMPHOMA; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRAIN; CELL CYCLE PROTEINS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; DNA-BINDING PROTEINS; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LDL-RECEPTOR RELATED PROTEIN 2; LYMPH NODES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALONDIALDEHYDE; METALLOTHIONEIN; MIDDLE AGED; NUCLEAR PROTEINS; OXIDATIVE STRESS; TYROSINE;

EID: 76349105076     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903518329     Document Type: Article

References (44)

1. Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics 2009;6:587-597.
2. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009;8:581-592.
3. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281-1288.
4. Mohile NA, Abrey LE. Primary central nervous system lymphoma. Semin Radiat Oncol 2007;17:223-229.
5. Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathol Lab Med 2008;132:118-124.
6. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 2009;44:29-64.
7. SjöLD, Poulsen CB, Hansen M, Møller MB, Ralfkiaer E. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol 2007;79:501-507.
8. Higgins RA, Blankenship JE, Kinney MC. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med 2008;132:441-461.
9. Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT. Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep 2009;11:73-80.
10. DeAngelis LM. Primary central nervous system lymphoma: coming or going? Blood 2009;113:4483-4484.
11. Sierra del Rio M, Rousseau A, Soussain C, Ricard D, Hoang- Xuan K. Primary CNS lymphoma in immunocompetent patients. Oncologist 2009;14:526-539.
12. Hochberg FH, Baehring JM, Hochberg EP. Primary CNS lymphoma. Nat Clin Pract Neurol 2007;3:24-35.
13. Poulsen CB, Borup R, Borregaard N, Nielsen FC, Møller MB, Ralfkiaer E. Prognostic significance of metallothionein in B-cell lymphomas. Blood 2006;108:3514-3519.
14. Yang M, Chitambar CR. Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med 2008;45:763-772.
15. Penkowa M, Sørensen BL, Nielsen SL, Hansen PB. Metallothionein as a useful marker in Hodgkin lymphoma subclassification. Leuk Lymphoma 2009;50:200-210.
16. Penkowa M, Espejo C, Ortega-Aznar A, et al. Metallothionein expression in the central nervous system of multiple sclerosis patients. Cell Mol Life Sci 2003;60:1258-1266.
17. Scheede Bergdahl C, Penkowa M, Hidalgo J, Olsen DB, Boushel R, Dela F. Metallothionein-mediated antioxidant defense system and its response to exercise training are impaired in human type 2 diabetes. Diabetes 2005;54:3089-3094.
18. McCann KJ, Ashton-Key M, Smith K, Stevenson FK, Ottensmeier CH. Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood 2009;113:4677-4680.
19. Camilleri-Broët S, Martin A, Moreau A, et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol 1998; 110:607-612.
20. Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006;106:128-135.
21. Kinoshita M, Izumoto S, Hashimoto N, et al. Immunohistochemical analysis of adhesion molecules and matrix metalloproteinases in malignant CNS lymphomas: a study comparing primary CNS malignant and CNS intravascular lymphomas. Brain Tumor Pathol 2008;25:73-78.
22. Robertus JL, Harms G, Blokzijl T, et al. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol 2009;22:547-555.
23. Nielsen AE, Bohr A, Penkowa M. The balance between life and death of cells: roles of metallothioneins. Biomark Insights 2007;2:99-111.
24. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M. Cell death in the injured brain: roles of metallothioneins. Prog Histochem Cytochem 2009;44:1-27.
25. Penkowa M. Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS J 2006;273:1857-1870.
26. Chung RS, Hidalgo J, West AK. New insight into the molecular pathways of metallothionein-mediated neuroprotection and regeneration. J Neurochem 2008;104: 14-20.
27. Bhagavathi S, Sharathkumar A, Hunter S, et al. Activated Bcell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas. Clin Neuropathol 2008;27:13-20.
28. Poulsen CB, Borup R, Nielsen FC, et al. Microarray-based classification of diffuse large B-cell lymphoma. Eur J Haematol 2005;74:453-465.
29. Chung RS, Penkowa M, Dittmann J, et al. Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyteneuron response to injury. J Biol Chem 2008;283:15349-15358.
30. Dutsch-Wicherek M, Sikora J, Tomaszewska R. The possible biological role of metallothionein in apoptosis. Front Biosci 2008;13:4029-4038.
31. Yang M, Kroft SH, Chitambar CR. Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther 2007;6:633-643.
32. Thirumoorthy N, Manisenthil Kumar KT, Shyam Sundar A, Panayappan L, Chatterjee M. Metallothionein: an overview. World J Gastroenterol 2007;13:993-996.
33. Miyashita H, Sato Y. Metallothionein 1 is a downstream target of vascular endothelial zinc finger 1 (VEZF1) in endothelial cells and participates in the regulation of angiogenesis. Endothelium 2005;12:163-170.
34. Cherian MG, Kang YJ. Metallothionein and liver cell regeneration. Exp Biol Med (Maywood) 2006;231:138-144.
35. Ostrakhovitch EA, Olsson PE, Jiang S, Cherian MG. Interaction of metallothionein with tumor suppressor p53 protein. FEBS Lett 2006;580:1235-1238.
36. Theocharis SE, Margeli AP, Koutselinis A. Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers 2003;18:162-169.
37. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP. Metallothionein expression in human neoplasia. Histopathology 2004;45:103-118.
38. Faurschou M, Penkowa M, Andersen CB, Starklint H, Jacobsen S. The renal metallothionein expression profile is altered in human lupus nephritis. Arthritis Res Ther 2008;10:R76.
39. Ambjørn M, Asmussen JW, Lindstam M, et al. Metallothionein and a peptide modeled after metallothionein, EmtinB, induce neuronal differentiation and survival through binding to receptors of the low-density lipoprotein receptor family. J Neurochem 2008;104:21-37.
40. Pedersen MØ, Jensen R, Pedersen DS, et al. Metallothionein- I+II in neuroprotection. Biofactors 2009;35:315-325.
41. Sauerbrey A, Zintl F, Volm M. Expression of metallothionein in initial and relapsed childhood acute lymphoblastic leukemia. Ann Hematol 1994;69:111-115. (Pubitemid 24284966)
42. Volm M, Zintl F, Edler L, Sauerbrey A. Prognostic value of protein kinase C, proto-oncogene products and resistancerelated proteins in newly diagnosed childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1997;28:117-126.
43. Fitzgerald M, Nairn P, Bartlett CA, Chung RS, West AK, Beazley LD. Metallothionein-IIA promotes neurite growth via the megalin receptor. Exp Brain Res 2007;183:171-180.
44. Chung RS, Hidalgo J, West AK. New insight into the molecular pathways of metallothionein-mediated neuroprotection and regeneration. J Neurochem 2008;104: 14-20.